## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

**WASHINGTON, D.C. 20549** 

FORM 8-K	
----------	--

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 19, 2023

# Graphite Bio, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction of Incorporation) 001-40532 (Commission File Number) 84-4867570 (IRS Employer Identification No.)

201 HASKINS WAY SUITE 210 SOUTH SAN FRANCISCO, California (Address of Principal Executive Offices)

94080 (Zip Code)

Registrant's Telephone Number, Including Area Code: 650 484-0886

(Former Name or Former Address, if Changed Since Last Report)

Che	Check the appropriate box below if the Form 8-K filing is intended to sim	nultaneously satisfy the	iling obligation of the registrant under any of the following provisions:				
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)						
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)						
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))						
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))						
	Securities registered pursuant to Section 12(b) of the Act:						
	Title of each class Common Stock	Trading Symbol(s) GRPH	Name of each exchange on which registered The Nasdaq Global Market				
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).							
Em	Emerging growth company ⊠						
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. $\Box$							

#### Item 5.07 Submission of Matters to a Vote of Security Holders.

The proposals set forth below were submitted to the stockholders at the Annual Meeting of Stockholders (the "Annual Meeting") of Graphite Bio, Inc. (the "Company") held on July 19, 2023, with each such proposal described in the Proxy Statement, filed by the Company on June 6, 2023.

The number of shares of common stock entitled to vote at the Annual Meeting was 58,102,949. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 44,107,052. The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each proposal voted upon are set forth below.

#### Proposal 1 - Election of Directors

The Company's stockholders elected the three (3) director nominees below to the Company's Board of Directors as Class II directors to hold office until the 2026 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified.

Director Nominee	Votes For	Votes Withheld
Abraham Bassan	36,301,366	2,250,503
Matthew Porteus, M.D., Ph.D.	35,885,476	2,666,393
Jo Viney, Ph.D.	36,373,878	2,177,991

There were 5,555,183 broker non-votes regarding this proposal.

#### Proposal 2 - Ratification of Appointment of Independent Registered Accounting Firm

The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023.

Votes For	Votes Against	Abstentions
44,039,995	11,869	55,188

There were zero broker non-votes regarding this proposal.

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Graphite Bio, Inc.

Date: July 20, 2023 By: /s/ Josh Lehrer
Josh Lehrer

**Josh Lehrer** Chief Executive Officer